A trial looking at vinflunine chemotherapy for advanced bladder, kidney or ureter cancer (L00070 IN 302 P1)

Cancer type:

Bladder cancer
Kidney cancer
Transitional cell cancer

Status:

Results

Phase:

Phase 3

This trial was comparing best supportive care and vinflunine with best supportive care alone for advanced cancer of the urinary tract.

The urinary tract includes the

Cancer that spreads to another part of the body is called advanced cancer. It is usually more difficult to treat. Doctors often give chemotherapy but sometimes the cancer continues to grow.

Some people have another course of chemotherapy (second line treatment) if their first course hasn’t helped. But there is no standard second line treatment for advanced cancer of the urinary tract, so treatment varies. Many people have what is called ‘best supportive care’. This means treatment to help with symptoms they are having.

Doctors thought that a chemotherapy drug called vinflunine might be useful for advanced urinary tract cancer. But they were not sure how well it would work.

The aim of this trial was to compare best supportive care and vinflunine with best supportive care alone, to see which was better as second line treatment for advanced urinary tract cancer.

Summary of results

The trial team found that on average, people who had vinflunine and best supportive care lived longer than people who had best supportive care alone.

The trial recruited 370 people who had already had other chemotherapy including a platinum drug

  • Two thirds had vinflunine and best supportive care
  • One third had best supportive care alone

On average, people having vinflunine had 3 cycles of treatment. The side effects included a drop in the number of blood cells, fatigue, constipation, mild hair loss and reactions at the injection site. Although fatigue is a common side effect of chemotherapy, in this trial the researchers found that nearly 1 in 5 people having best supportive care alone also had fatigue.

The average length of time that people lived after treatment was more than 2 and a half months longer in the group who had vinflunine.

From these results, the researchers say that vinflunine could become a standard second line treatment for cancer of the urinary tract.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed) but may not have been published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof Nick James

Supported by

Pierre Fabre Medicament

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 404

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page